1. Home
  2. CTKB vs TRDA Comparison

CTKB vs TRDA Comparison

Compare CTKB & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • TRDA
  • Stock Information
  • Founded
  • CTKB 1990
  • TRDA 2016
  • Country
  • CTKB United States
  • TRDA United States
  • Employees
  • CTKB N/A
  • TRDA 183
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • TRDA Health Care
  • Exchange
  • CTKB Nasdaq
  • TRDA Nasdaq
  • Market Cap
  • CTKB 433.8M
  • TRDA 264.4M
  • IPO Year
  • CTKB 2021
  • TRDA 2021
  • Fundamental
  • Price
  • CTKB $3.90
  • TRDA $6.63
  • Analyst Decision
  • CTKB Hold
  • TRDA Strong Buy
  • Analyst Count
  • CTKB 4
  • TRDA 3
  • Target Price
  • CTKB $6.00
  • TRDA $25.67
  • AVG Volume (30 Days)
  • CTKB 650.8K
  • TRDA 187.5K
  • Earning Date
  • CTKB 11-05-2025
  • TRDA 11-06-2025
  • Dividend Yield
  • CTKB N/A
  • TRDA N/A
  • EPS Growth
  • CTKB N/A
  • TRDA N/A
  • EPS
  • CTKB N/A
  • TRDA N/A
  • Revenue
  • CTKB $196,035,000.00
  • TRDA $79,476,000.00
  • Revenue This Year
  • CTKB N/A
  • TRDA N/A
  • Revenue Next Year
  • CTKB $7.25
  • TRDA N/A
  • P/E Ratio
  • CTKB N/A
  • TRDA N/A
  • Revenue Growth
  • CTKB N/A
  • TRDA N/A
  • 52 Week Low
  • CTKB $2.37
  • TRDA $4.93
  • 52 Week High
  • CTKB $7.63
  • TRDA $21.79
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 47.24
  • TRDA 54.36
  • Support Level
  • CTKB $3.71
  • TRDA $6.60
  • Resistance Level
  • CTKB $4.42
  • TRDA $7.54
  • Average True Range (ATR)
  • CTKB 0.19
  • TRDA 0.42
  • MACD
  • CTKB -0.03
  • TRDA 0.02
  • Stochastic Oscillator
  • CTKB 25.35
  • TRDA 50.68

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: